SCYNEXIS, Inc.

NasdaqGM:SCYX 주식 보고서

시가총액: US$75.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SCYNEXIS 관리

관리 기준 확인 2/4

SCYNEXIS' CEO는 David Angulo, Jan2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 $ 1.21M, 46.5% 로 구성됩니다. 46.5% 급여 및 53.5% 보너스(회사 주식 및 옵션 포함). 는 $ 226.70K 가치에 해당하는 회사 주식의 0.32% 직접 소유합니다. 226.70K. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 9 년입니다.

주요 정보

David Angulo

최고 경영자

US$1.2m

총 보상

CEO 급여 비율46.5%
CEO 임기1.5yrs
CEO 소유권0.3%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간9.1yrs

최근 관리 업데이트

Recent updates

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

CEO 보상 분석

David Angulo 의 보수는 SCYNEXIS 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

US$101m

Dec 31 2023US$1mUS$565k

US$67m

Sep 30 2023n/an/a

US$72m

Jun 30 2023n/an/a

US$44m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$1mUS$482k

-US$63m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$987kUS$461k

-US$33m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$939kUS$447k

-US$55m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$437k

-US$54m

Sep 30 2019n/an/a

-US$37m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$769kUS$424k

-US$12m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$768kUS$412k

-US$25m

보상 대 시장: David 의 총 보상 ($USD 1.21M )은 US 시장( $USD 683.56K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Angulo (59 yo)

1.5yrs

테뉴어

US$1,214,710

보상

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....

리더십 팀

이름위치테뉴어보상소유권
David Angulo
CEO, President & Director1.5yrsUS$1.21m0.32%
$ 239.9k
Ivor Macleod
Chief Financial Officer1.8yrsUS$626.90k0.028%
$ 21.0k
Scott Sukenick
Chief Legal Officer & Corporate Secretary6.7yrsUS$936.70k0.21%
$ 159.7k
Daniella Gigante
Vice President of Human Resources & Information Technologyno data데이터 없음데이터 없음

1.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: SCYX 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
David Angulo
CEO, President & Director1.5yrsUS$1.21m0.32%
$ 239.9k
Armando Anido
Independent Director5.5yrsUS$98.75k0.066%
$ 50.0k
David Hastings
Independent Director8.8yrsUS$104.25k0.061%
$ 46.4k
Ann Hanham
Independent Director15.6yrsUS$105.25k0.063%
$ 47.2k
Guy MacDonald
Independent Chairman of the Board9.7yrsUS$128.75k0.085%
$ 64.0k
Steven Gilman
Independent Director9.4yrsUS$106.25k0.064%
$ 48.0k
David Denning
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Peter Pappas
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Oliver Cornely
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Barbara Alexander
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Mahmoud Ghannoum
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Paul Nyirjesy
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

9.1yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: SCYX 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.